The CEO Follows His Director in With $2.6M
A few hours after a director stepped in, the CEO of this cancer-drug developer put down $2.6 million at $105.82, and that's the buy that carries the weight. Mark Lappe has now bought this name five times in the past year, which tells you he's not timing a bounce so much as building a position through the clinical grind. Insider buys here have worked about two-thirds of the time over 30 days, though the 90-day picture flattens out, so the edge fades if you overstay. Price is sitting below the 8-day at $114 with the 20-day underneath at $112, so the tape hasn't confirmed yet. Support is down at $86.40 if this pulls back, and that's where patience pays over chasing.
The Filing
| Ticker | INBX |
| Company | Inhibrx Biosciences, Inc. |
| Insider | Mark Lappe, Chief Executive Officer |
| Buy amount | $2.6M |
| Filing date | September 8, 2026 |
| Conviction | Interesting · 51/100 |
| Setup type | Trend Confirmation |
Ultimate members received this analysis in real time.